Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:44pm, Tuesday, 30'th Sep 2025
LOS ANGELES , Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June
Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors
03:24pm, Tuesday, 30'th Sep 2025
LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc., ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action on behalf of investors that bough
Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT
10:52am, Tuesday, 30'th Sep 2025
LOS ANGELES--(BUSINESS WIRE)--Altimmune, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ALT.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
10:20am, Tuesday, 30'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
PHILADELPHIA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) (“Altimmune” or t
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
02:56pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
08:45am, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful fra
NEW YORK, Sept. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
09:00am, Friday, 26'th Sep 2025
NEW YORK , Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
PHILADELPHIA , Sept. 25, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a�
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
10:30am, Thursday, 25'th Sep 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
